{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T05:59:12Z","timestamp":1790056752395,"version":"4.0.1"},"reference-count":37,"publisher":"Informa UK Limited","issue":"7","license":[{"start":{"date-parts":[[2018,7,3]],"date-time":"2018-07-03T00:00:00Z","timestamp":1530576000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"content-domain":{"domain":["www.tandfonline.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2018,7,3]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Malignant mesothelioma is an asbestos-related aggressive tumor and current therapy remains ineffective. Zebularine as a DNA methyltransferase (DNMT) inhibitor has an anti-tumor effect in several human cancer cells. The aim of the present study was to investigate whether zebularine could induce antiproliferative effect in human malignant mesothelioma cells. Zebularine induced cell growth inhibition in a dose-dependent manner. In addition, zebularine dose-dependently decreased expression of DNMT1 in all malignant mesothelioma cells tested. Cell cycle analysis indicated that zebularine induced S phase delay. Zebularine also induced cell death in malignant mesothelioma cells. In contrast, zebularine did not induce cell growth inhibition and cell death in human normal fibroblast cells. These results suggest that zebularine has a potential for the treatment of malignant mesothelioma by inhibiting cell growth and inducing cell death.<\/jats:p>","DOI":"10.1080\/09168451.2018.1459466","type":"journal-article","created":{"date-parts":[[2018,4,24]],"date-time":"2018-04-24T03:49:46Z","timestamp":1524541786000},"page":"1159-1164","update-policy":"https:\/\/doi.org\/10.1080\/tandf_crossmark_01","source":"Crossref","is-referenced-by-count":14,"title":["Zebularine exerts its antiproliferative activity through S phase delay and cell death in human malignant mesothelioma cells"],"prefix":"10.1080","volume":"82","author":[{"given":"Yukitoshi","family":"Takemura","sequence":"first","affiliation":[{"name":"Institute of Industrial Science, The University of Tokyo , Tokyo, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Motohiko","family":"Satoh","sequence":"additional","affiliation":[{"name":"Institute of Industrial Science, The University of Tokyo , Tokyo, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenichi","family":"Hatanaka","sequence":"additional","affiliation":[{"name":"Institute of Industrial Science, The University of Tokyo , Tokyo, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shunichiro","family":"Kubota","sequence":"additional","affiliation":[{"name":"Institute of Industrial Science, The University of Tokyo , Tokyo, Japan"},{"name":"Department of Pharmaceutical Sciences, Teikyo Heisei University , Tokyo, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"301","published-online":{"date-parts":[[2018,7,3]]},"reference":[{"key":"2021040104595823800_CIT0001","doi-asserted-by":"publisher","first-page":"2098","DOI":"10.1016\/j.addr.2013.05.011","article-title":"Genotoxicity and carcinogenicity risk of carbon nanotubes","volume":"65","author":"Toyokuni","year":"2013","journal-title":"Adv Drug Deliv Rev"},{"key":"2021040104595823800_CIT0002","doi-asserted-by":"publisher","first-page":"475","DOI":"10.1038\/nrc.2017.42","article-title":"Novel insights into mesothelioma biology and implications for therapy","volume":"17","author":"Yap","year":"2017","journal-title":"Nat Rev Cancer"},{"key":"2021040104595823800_CIT0003","doi-asserted-by":"publisher","first-page":"1148","DOI":"10.1056\/NEJMra072067","article-title":"Epigenetics in cancer","volume":"358","author":"Esteller","year":"2008","journal-title":"N Engl J Med"},{"key":"2021040104595823800_CIT0004","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1016\/j.ccr.2012.06.008","article-title":"Cancer genetics and epigenetics: two sides of the same coin?","volume":"22","author":"You","year":"2012","journal-title":"Cancer Cell"},{"key":"2021040104595823800_CIT0005","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1016\/j.lungcan.2013.05.014","article-title":"The role of epigenetics in malignant pleural mesothelioma","volume":"81","author":"Vandermeers","year":"2013","journal-title":"Lung Cancer"},{"key":"2021040104595823800_CIT0006","first-page":"2989","article-title":"DNA methyltransferase inhibitors and their emerging role in epigenetic therapy of cancer","volume":"33","author":"Gnyszka","year":"2013","journal-title":"Anticancer Res"},{"key":"2021040104595823800_CIT0007","doi-asserted-by":"publisher","first-page":"166","DOI":"10.1016\/j.critrevonc.2017.01.020","article-title":"Epigenetic control of gene expression: potential implications for cancer treatment","volume":"111","author":"Perri","year":"2017","journal-title":"Crit Rev Oncol Hematol"},{"key":"2021040104595823800_CIT0008","doi-asserted-by":"publisher","first-page":"830","DOI":"10.1016\/0006-2952(80)90566-3","article-title":"Inhibition of cytidine deaminase by 2-oxopyrimidine riboside and related compounds","volume":"29","author":"McCormack","year":"1980","journal-title":"Biochem Pharmacol"},{"key":"2021040104595823800_CIT0009","doi-asserted-by":"publisher","first-page":"662","DOI":"10.1021\/jm00138a003","article-title":"Cyclic urea nucleosides. Cytidine deaminase activity as a function of aglycon ring size","volume":"24","author":"Liu","year":"1981","journal-title":"J Med Chem"},{"key":"2021040104595823800_CIT0010","doi-asserted-by":"publisher","first-page":"2280","DOI":"10.1016\/j.biochi.2012.07.025","article-title":"DNA methylation inhibitors in cancer: Recent and future approaches","volume":"94","author":"Gros","year":"2012","journal-title":"Biochimie"},{"key":"2021040104595823800_CIT0011","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1093\/jnci\/95.5.399","article-title":"Inhibition of DNA methylation and reactivation of silenced genes by zebularine","volume":"95","author":"Cheng","year":"2003","journal-title":"J Natl Cancer Inst"},{"key":"2021040104595823800_CIT0012","doi-asserted-by":"publisher","first-page":"3862","DOI":"10.1158\/1078-0432.CCR-04-2406","article-title":"Plasma pharmacokinetics, oral bioavailability, and interspecies scaling of the DNA methyltransferase inhibitor, zebularine","volume":"11","author":"Holleran","year":"2005","journal-title":"Clin Cancer Res"},{"key":"2021040104595823800_CIT0013","doi-asserted-by":"publisher","first-page":"581","DOI":"10.1007\/s10549-009-0420-3","article-title":"Effects of a novel DNA methyltransferase inhibitor zebularine on human breast cancer cells","volume":"120","author":"Billam","year":"2010","journal-title":"Breast Cancer Res Treat"},{"key":"2021040104595823800_CIT0014","doi-asserted-by":"publisher","first-page":"847","DOI":"10.1002\/mc.v53.11","article-title":"Zebularine inhibits the growth of A549 lung cancer cells via cell cycle arrest and apoptosis","volume":"53","author":"You","year":"2014","journal-title":"Mol Carcinog"},{"key":"2021040104595823800_CIT0015","doi-asserted-by":"publisher","first-page":"e0120545","DOI":"10.1371\/journal.pone.0120545","article-title":"DNA methyltransferase inhibitor zebularine induces human cholangiocarcinoma cell death through alteration of DNA methylation status","volume":"10","author":"Nakamura","year":"2015","journal-title":"PLoS One"},{"key":"2021040104595823800_CIT0016","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1007\/s10637-016-0401-4","article-title":"The DNA methyltransferase inhibitor zebularine exerts antitumor effects and reveals BATF2 as a poor prognostic marker for childhood medulloblastoma","volume":"35","author":"Andrade","year":"2017","journal-title":"Invest New Drugs"},{"key":"2021040104595823800_CIT0017","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1111\/cas.2006.97.issue-5","article-title":"Establishment and characterization of four malignant pleural mesothelioma cell lines from Japanese patients","volume":"97","author":"Usami","year":"2006","journal-title":"Cancer Sci"},{"key":"2021040104595823800_CIT0018","first-page":"507","article-title":"Origin of heterogeneity of interleukin-6 (IL-6) levels in malignant pleural effusions","volume":"1","author":"Yokoyama","year":"1994","journal-title":"Oncol Rep"},{"key":"2021040104595823800_CIT0019","doi-asserted-by":"publisher","first-page":"414","DOI":"10.1038\/embor.2013.25","article-title":"Another fork in the road \u2013 life or death decisions by the tumour suppressor p53","volume":"14","author":"Carvajal","year":"2013","journal-title":"EMBO Rep"},{"key":"2021040104595823800_CIT0020","doi-asserted-by":"publisher","first-page":"1912","DOI":"10.3390\/biom5031912","article-title":"Targeting the checkpoint to kill cancer cells","volume":"5","author":"Benada","year":"2015","journal-title":"Biomolecules"},{"key":"2021040104595823800_CIT0021","doi-asserted-by":"publisher","first-page":"594","DOI":"10.1038\/nrc864","article-title":"Live or let die: the cell\u2019s response to p53","volume":"2","author":"Vousden","year":"2002","journal-title":"Nat Rev Cancer"},{"key":"2021040104595823800_CIT0022","doi-asserted-by":"publisher","first-page":"7644","DOI":"10.1038\/sj.onc.1203015","article-title":"Regulation of p53 in response to DNA damage","volume":"18","author":"Lakin","year":"1999","journal-title":"Oncogene"},{"key":"2021040104595823800_CIT0023","doi-asserted-by":"publisher","first-page":"889","DOI":"10.1016\/j.dnarep.2004.03.029","article-title":"DNA damage-induced activation of ATM and ATM-dependent signaling pathways","volume":"3","author":"Kurz","year":"2004","journal-title":"DNA Repair"},{"key":"2021040104595823800_CIT0024","doi-asserted-by":"publisher","first-page":"14985","DOI":"10.1074\/jbc.M213219200","article-title":"Knockdown of DNA methyltransferase 1 triggers an intra-S-phase arrest of DNA replication and induction of stress response genes","volume":"278","author":"Milutinovic","year":"2003","journal-title":"J Biol Chem"},{"key":"2021040104595823800_CIT0025","doi-asserted-by":"publisher","first-page":"7575","DOI":"10.1128\/MCB.01887-05","article-title":"DNA methyltransferase 1 knockdown activates a replication stress checkpoint","volume":"26","author":"Unterberger","year":"2006","journal-title":"Mol Cell Biol"},{"key":"2021040104595823800_CIT0026","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1016\/j.bcp.2005.04.010","article-title":"Metabolic activation of zebularine, a novel DNA methylation inhibitor, in human bladder carcinoma cells","volume":"70","author":"Ben-Kasus","year":"2005","journal-title":"Biochem Pharmacol"},{"key":"2021040104595823800_CIT0027","doi-asserted-by":"publisher","first-page":"1788","DOI":"10.1105\/tpc.114.135467","article-title":"Repair of DNA damage induced by the cytidine analog zebularine requires ATR and ATM in arabidopsis","volume":"27","author":"Liu","year":"2015","journal-title":"Plant Cell"},{"key":"2021040104595823800_CIT0028","doi-asserted-by":"publisher","first-page":"e12388","DOI":"10.1371\/journal.pone.0012388","article-title":"Mechanistic insights on the inhibition of C5 DNA methyltransferases by zebularine","volume":"5","author":"Champion","year":"2010","journal-title":"PLoS One"},{"key":"2021040104595823800_CIT0029","doi-asserted-by":"publisher","first-page":"4122","DOI":"10.4161\/cc.21997","article-title":"Putting the brakes on p53-driven apoptosis","volume":"11","author":"H\u00f6pker","year":"2012","journal-title":"Cell Cycle"},{"key":"2021040104595823800_CIT0030","doi-asserted-by":"publisher","first-page":"3219","DOI":"10.1038\/srep03219","article-title":"Zebularine inhibits tumorigenesis and stemness of colorectal cancer via p53-dependent endoplasmic reticulum stress","volume":"3","author":"Yang","year":"2013","journal-title":"Sci Rep"},{"key":"2021040104595823800_CIT0031","doi-asserted-by":"publisher","first-page":"e54036","DOI":"10.1371\/journal.pone.0054036","article-title":"DNA methyltransferase inhibitor zebularine inhibits human hepatic carcinoma cells proliferation and induces apoptosis","volume":"8","author":"Nakamura","year":"2013","journal-title":"PLoS One"},{"key":"2021040104595823800_CIT0032","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1139\/o97-053","article-title":"New aspects of the mechanism of DNA fragmentation in apoptosis","volume":"75","author":"Walker","year":"1997","journal-title":"Biochem Cell Biol"},{"key":"2021040104595823800_CIT0033","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1016\/B978-0-12-385493-3.00004-8","article-title":"Apoptosis and beyond: cytometry in studies of programmed cell death","volume":"103","author":"Wlodkowic","year":"2011","journal-title":"Methods Cell Biol"},{"key":"2021040104595823800_CIT0034","doi-asserted-by":"crossref","first-page":"8924","DOI":"10.18632\/oncotarget.2441","article-title":"Selected drugs that inhibit DNA methylation can preferentially kill p53 deficient cells","volume":"5","author":"Yi","year":"2014","journal-title":"Oncotarget"},{"key":"2021040104595823800_CIT0035","doi-asserted-by":"publisher","first-page":"1270","DOI":"10.1128\/MCB.24.3.1270-1278.2004","article-title":"Continuous zebularine treatment effectively sustains demethylation in human bladder cancer cells","volume":"24","author":"Cheng","year":"2004","journal-title":"Mol Cell Biol"},{"key":"2021040104595823800_CIT0036","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1016\/j.lungcan.2006.06.017","article-title":"Promoter methylation of RASSF1A, RAR\u03b2 and DAPK predict poor prognosis of patients with malignant mesothelioma","volume":"54","author":"Fischer","year":"2006","journal-title":"Lung Cancer"},{"key":"2021040104595823800_CIT0037","doi-asserted-by":"publisher","first-page":"220","DOI":"10.1016\/j.lungcan.2007.06.015","article-title":"DNA methylation profile of 28 potential marker loci in malignant mesothelioma","volume":"58","author":"Tsou","year":"2007","journal-title":"Lung Cancer"}],"container-title":["Bioscience, Biotechnology, and Biochemistry"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/bbb\/article-pdf\/82\/7\/1159\/36844781\/bbb1159.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/academic.oup.com\/bbb\/article-pdf\/82\/7\/1159\/36844781\/bbb1159.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,6,7]],"date-time":"2022-06-07T07:48:20Z","timestamp":1654588100000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/bbb\/article\/82\/7\/1159\/5938749"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,7,3]]},"references-count":37,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2018,7,3]]},"published-print":{"date-parts":[[2018,7,3]]}},"URL":"https:\/\/doi.org\/10.1080\/09168451.2018.1459466","relation":{},"ISSN":["0916-8451","1347-6947"],"issn-type":[{"value":"0916-8451","type":"print"},{"value":"1347-6947","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2018,7,3]]},"published":{"date-parts":[[2018,7,3]]},"assertion":[{"value":"The publishing and review policy for this title is described in its Aims & Scope.","order":1,"name":"peerreview_statement","label":"Peer Review Statement"},{"value":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=tbbb20","URL":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=tbbb20","order":2,"name":"aims_and_scope_url","label":"Aim & Scope"},{"value":"2018-02-07","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2018-03-20","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2018-04-24","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}